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Nucleoside analogue reverse transcriptase inhibitors (NRTIs)
are effective antiretroviral therapies for the treatment of HIV-
infected patients. Treatment with NRTIs has been associated
with mitochondrial toxicity [1] responsible for adverse events
including hepatic steatosis [2], myopathy [3], neuropathy [4],
myelotoxicity [5] and overproduction of lactate [1].
Symptomatic lactic acidosis following the use of NRTIs was
first described by Jolliet and Widmann [6] and by Chatta and
colleagues [7] in HIV-infected patients treated with azido-
thymidine. Several reports since then have established that
other NRTIs can induce lactic acidosis [8–30]. This severe
adverse event is infrequent but its occurrence may be under-
estimated [31]. Progression of lactic acidosis can lead to irre-
versible multiple organ failure despite drug withdrawal [8].
In the present review, based on Medline research and using
personal data, we describe the pathophysiology and the clin-
ical spectrum of lactic acidosis in an attempt to define a pop-
ulation with a poor prognosis. Based on clinical data and
experimental evidence, we discuss the use of L-carnitine as
a specific treatment for life-threatening NRTI-induced lactic
acidosis.
Mitochondrial functions and NRTI toxicity
Mitochondrial respiratory chain
The main function of mitochondria is to produce energy
through electron-chain transport and oxidative phosphorylation
(summarised in Fig.1). The core of the pathway is a complex
of five subunits (subunits I–V) located on the inner mitochon-
drial membrane. Electrons pass the chain from various sub-
strates, providing energy to the proton pump that creates an
electrochemical gradient between mitochondria and their envi-
ronment. Different substrates can enter the electron-chain
transport at complex I (the reduced form of nicotinamide
adenine dinucleotide [NADH]–coenzyme Q oxidoreductase)
or complex II (succinate–coenzyme Q oxidoreductase), which
provide electrons to complex III (coenzyme QH2–cytochrome
oxidoreductase). Complex III then reduces cytochrome c,
which passes electrons to complex IV (cytochrome c oxidase).
Complex V (ATP synthase) produces ATP.
To feed this chain, degradative metabolic pathways transform
substrates into energetic compounds. The oxidative decar-
boxylation of pyruvate leads to the production of acetyl-
coenzyme A. Fatty acids enter the mitochondrial metabolism
after β-oxidation, which allows the production of two acetyl-
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Abstract
Nucleoside reverse transcriptase inhibitors (NRTIs) are effective antiretroviral therapy for the treatment
of HIV-infected patients. NRTIs can induce mitochondrial impairment that leads to a number of adverse
events, including symptomatic lactic acidosis. In the present review, we describe the underlying
mechanism of NRTI-induced toxicity and the main clinical features of this infrequent, but severe,
emerging complication. We also summarise experimental data and clinical observations that support
the use of L-carnitine supplementation to reverse NRTI-induced mitochondrial impairment.
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coenzyme A molecules and one acyl-coenzyme A molecule
shorter than the initial substrate. Acetyl-coenzyme A then
enters the citric acid cycle or Krebs cycle to release carbon
dioxide, hydrogen, NADH, the reduced form of flavine
adenine dinucleotide (FADH2), GTP and coenzyme A.
Mechanisms of NRTI-induced lactate elevation
The toxicity of NRTI is related to alterations of the mitochon-
drial breathing pathway at different levels. The mechanisms of
toxicity related to the use of NRTI are summarised in Table 1.
Longstanding use of NRTI induces damage of βDNA and
γDNA polymerases. The dysfunction of γDNA polymerase
leads to mitochondrial accumulation of abnormal nucleoside
acids that alter termination and internalisation of mitochondr-
ial DNA [32]. A recent article confirms that mitochondrial
DNA levels are significantly decreased in patients with symp-
tomatic, nucleoside-related hyperlactataemia, and confirms
that reduction of mitochondrial DNA precedes symptomatic
hyperlactataemia and resolves on the discontinuation of
therapy [33].Nevertheless, another report states that, despite
the mitochondrialDNA depletion, the oxidative capacity of the
mitochondrial respiratory chain is preserved in lymphocytes
derived from treated asymptomatic HIV-infectedpatients. This
does not exclude the possibility of decreased mitochondrial
respiratory-chain function in other tissues [34].
As mitochondrial DNA encodes 13 out of 80 enzymes of the
breathing pathway, this dysregulation leads to the decrease
in ATP synthesis and metabolism. In addition, NRTIs also
decrease electron transfer by impairing the NAD+/NADH
cycle [35].
NRTIs thus impair the β-oxidation cycle and disrupt oxidative
phosphorylation [1]. These pathways physiologically allow
fatty acids and pyruvate to enter as energetic substrates in
the mitochondrion. When NRTI toxicity occurs, long-chain
fatty acids (characterised by a carbon scaffold above
12 residues) do not contribute to ATP production and accu-
mulate into the cytosol of myocytes and hepatocytes. An
increase in glycolysis then leads to the overproduction of
lactic acid, which imbalances the lactate:pyruvate ratio [36].
The hepatic failure sometimes observed in this context com-
promises clearance of lactate and contributes to the develop-
ment of what is then classified as type II lactic acidosis (i.e.
related to the deregulation of cell metabolism and not directly
linked to tissue hypoxaemia).
Apoptosis, the programmed cell death phenomenon driven by
specific signalling pathways (reviewed in [37]) in response to
stress conditions, also contributes to NRTI toxicity. This phys-
iologic event is tightly regulated by the balance between
proapoptotic and antiapoptotic signals. The imbalance in
Figure 1
Mitochondrial electron chain transport and oxydative phosphorylation. Most of the energy produced by metabolic pathways is contained in the reduced
form of nicotinamide adenine dinucleotide (NADH) and in the reduced form of flavine adenine dinucleotide (FADH2), and is transformed in ATP by
mitochondria. Reduced mitochondrial coenzymes give their two electrons to carriers that carry them to molecular oxygen, the final electron acceptor,
using oxydo-reduction reactions. A protonic gradient allows hydrogen to cross the inner membrane and produce ATP. a-Cu, coenzyme a-copper; a3-
Cu, coenzyme 13-copper; CoA, coenzyme A; CoQ, coenzyme Q; Cyt, cytochrome; F0, F0 family ATP synthase; F1, F1 family ATP synthase; Fe-S, iron-
suphur cluster; FMN, flavine-adenine mononucleotide; H, hydrogen; LDH, lactate dehydrogenase; PDH, pyruvate dehydrogenase.228
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favour of proapoptotic signals can lead to activation of cas-
pases, the cysteine proteases that cleave target proteins to
determine apoptosis. Several studies suggest that NRTIs play
a proapoptotic role. In B-lymphoid cell types [38,39] and
peripheral blood mononuclear cells [40], azidothymidine can
trigger apoptosis and inhibition of the cell cycle [39] associ-
ated with overexpression of the death domain receptor Fas
[40], although it is established that mitochondrial apoptosis
can be responsible for an increased lactate production [41].
Clinical features of NRTI-induced lactic
acidosis in HIV-infected adults
Although the incidence of symptomatic lactic acidosis in
adult HIV-infected patients treated with NRTIs may have been
previously underestimated, recent data suggest that the
occurrence of NRTI-induced lactic acidosis is increasing
[31]. The estimated incidence varies between 1.3/1000 in
1995 [9] and 14.8/1000 recently [28], but this discrepancy
may be related to differences in case definition [31]. Descrip-
tions of clinical features and laboratory findings are sparse
and the literature does not precisely define the clinical spec-
trum of this disorder.
To identify the clinical features of NRTI-induced lactic acido-
sis in HIV-infected adults, we recently reviewed charts from
published observations and personal cases [42]. Twenty
patients were survivors and 19 patients did not survive the
disorder. The occurrence of symptomatic lactic acidosis or
hepatic failure attributed to the use of NRTIs in adult HIV-
infected patients defines severe mitochondrial cytopathy.
Although this disorder often occurs in overweight females, no
risk factor has been clearly identified. Most patients are diag-
nosed with AIDS at the time of the occurrence of the adverse
event. Cases have been attributed to the use of all NRTIs cur-
rently used in human therapy, although they seem to occur
more frequently when stavudine and lamivudine are com-
bined. The average delay between the introduction of NRTI
and the diagnosis of mitochondrial cytopathy is 8 months .
The time from admission to death was 5 days (range 1–17
days) in the nonsurvivor population.
Clinical manifestations are often nonspecific (summarized in
Table 2. Asthaenia is encountered in 70% of cases. Anorexia
(40%) and weight loss (20%) are also commonly reported.
The body temperature is normal in 50% of the cases, but it
can range between 35.3 and 39°C for the remaining patients.
Abdominal signs are reported in most patients: nausea and
vomiting are frequent (87.5%), as is abdominal pain (82%),
often localised in the right upper quadrant. Examination finds
hepatomegaly (75%), confirmed by ultrasound tomography
findings consistent with hepatic steatosis. Muscular weak-
ness is reported in 20% of the cases. Tachypnoea is very
common (83% of the cases) and mostly related to severe aci-
dosis.
Lactic acidosis is indeed a constant biological feature of mito-
chondrial cytopathy. The first recorded arterial blood lactate
concentration ranges between 2.9 and 43mmol/l, and life-
threatening acidosis occurs in 42% of the cases. Enzyme
liver assays show marked cytolysis (79%) and anicteric
cholestasis (73%). The prothrombin time is significantly
decreased in 45% of the patients. Other common laboratory
test abnormalities include elevated pancreatic enzymes
(33%) and increased creatine phosphokinase or lacticodehy-
drogenase concentrations. The liver is constantly involved,
and pathology examination usually reveals steatosis (n=11)
that can be classified as macrovacuolar, microvacuolar or
mixed. Electronic microscopy of the liver, when available
[8,12], shows ballonised mitochondria with loss of cristae.
Inflammation and necrosis of the pancreas gland are also
Table 1
Cellular effects of nucleosidic reverse transcriptase inhibitors (NRTIs) and carnitine
Toxicity of NRTIs References Effect of carnitine References
Metabolism Impairment of β-oxidation cycle [1] Long-chain fatty acids carrier [55]
Accumulation of long-chain fatty acids into the cytosol [34] Protection of cytochrome c oxidase from octanoic [61]
acid-induced damage
Decrease in ATP concentration [32] Cofactor of the electron chain from complex I–V [60]
Decreased electron-chain transport [32]
γDNA polymerase damage [33]
NAD+/NADH impairment
Apoptosis Increased apoptosis [36–38] Decreased global apoptosis [44–46]
Overexpression of the receptor Fas [38] Decreased ceramide generation [46,49–52]
Decreased mitochondrial apoptosis [49]
Link with Bcl2? [50]
NAD+, nicotinamide adenine dinucleotide; NADH, reduced form of nicotinamide adenine dinucleotide229
described. Lung pathology mostly indicates nonspecific
inflammatory oedema. Light microscopy never shows any
involvement of skeletal muscles in this setting.
The outcome of NRTI-induced lactic acidosis is often
unfavourable. Uncontrolled shock and/or hepatic failure
usually leads to death within 8 days following hospital admis-
sion. Supportive care including haemodialysis, alkalinisation,
vasoactive drugs and mechanical ventilation is inefficient. In
some cases, patients have been treated with prostaglandin
[13] and with thiamine [15] without any improvement.
In an attempt to identify prognostic factors, we compared
available data and the clinical course from hospital charts of
survivors and of nonsurvivors [43]. Clinical features did not
differ between the two populations. Conversely, arterial blood
pH and bicarbonates almost reached statistical significance,
probably because of the limited number of available observa-
tions. In fact, the first registered blood lactate was signifi-
cantly different between survivors and nonsurvivors. The
mean values of the initial blood lactate level in survivors and in
nonsurvivors were 7.3±3.8 and 18.6±8.8mmol/l, respec-
tively (P<0.01). We used the LOWESS smoothing function
and the locally weighted least-squares method to identify a
blood lactates threshold that is likely to predict poor outcome.
A value of 9mmol/l was associated with a positive predictive
value of 82%, with a negative predictive value of 94.5%, and
with high sensitivity and specificity.
The initial blood lactate level can thus predict the course in
symptomatic lactic acidosis related to the use of NRTIs.
Blood lactate below 9mmol/l at diagnosis is associated with
a less severe disorder, whereas a value above this threshold
is predictive of a fatal outcome.
L-carnitine as a possible treatment for NRTI-
induced severe lactic acidosis in HIV-infected
patients
Rationale for the use of L-carnitine in NRTI-induced
lactic acidosis
Carnitine is derived from γ-hydroxy-β-butyric acid. Although a
regular diet is the primary supply of carnitine, endogenous
synthesis is possible from sulphated amino acids (reviewed in
[44]). Carnitine levels are decreased in HIV-infected patients
through several mechanisms, including malabsorption,
increased excretion, overconsumption of energy in fatty acids
metabolism and the use of drugs, including NRTIs [44,45].
Carnitine is a pivotal cofactor for mitochondrial aerobic
metabolism [46]. It carries long-chain fatty acids through the
inner mitochondrial membrane to allow their use in the
β-oxidation circle. It also interacts downstream at different
steps as a cofactor between complex I–complex V of the
electron chain [47]. Carnitine directly stimulates phase IV of
the mitochondrial breathing cycle, and prevents the detrimen-
tal effect of octanoic acid on the cytochrome c oxidase [48].
An emerging concept suggests that carnitine could also mod-
ulate apoptosis. Carnitine decreases the number of apoptotic
cells and lowers caspase 3-like activity in Jurkat T cells after
stimulation of the death domain receptor Fas [49], in the
serum-starved P19 teratoma cell line [50] and in cardio-
myocytes exposed to doxorubicin [51]. In the latter model,
L-carnitine seems to lower the doxorubicin-induced sphyngo-
myelinase activity and decreases the concentration of
ceramides, messengers involved in programmed cell death.
Fibroblasts deficient for carnitine palmitoyl transferase 1, the
enzyme that converts carnitine into palmitoylcarnitine, are
resistant to apoptosis induced by staurosporine [52], a drug
that triggers the mitochondrial apoptotic pathway by opening
mitochondria transition pores. In addition, a clear association
between carnitine palmitoyl transferase 1 and the antiapop-
totic mitochondrial protein Bcl2 has been found using several
techniques including a yeast two-hybrid system [53]. These
data suggest that L-carnitine modulates apoptosis at the
mitochondrial level.
L-carnitine reverses the mitochondrial toxicity of NRTIs
in vitro. Incubation of cell lineages with NRTIs reproduces
features encountered in human NRTI-related cytopathy (i.e.
modification of the ultrastructure of the mitochondria and
accumulation of lipid droplets in the cytoplasm) [54]. In
human myotube cultures, the addition of carnitine in the
medium improves these changes whether or not azidothymi-
dine is withdrawn [55]. A clinical study confirmed the anti-
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Table 2
Common findings in 39 cases of nucleosidic reverse
transcriptase inhibitor-induced lactic acidosis
Clinical feature Percent of cases
Asthaenia 70
Muscular weakness 20
Anorexia 40
Loss of weight 20
Fever or hypothermia 50
Nausea and vomiting 87.5
Abdominal pain 82
Hepatomegaly 75
Tachypnea 83
Laboratory findings
Hyperlactataemia and metabolic acidosis 100
Hepatic cytolysis 79
Hepatic cholestasis 73
Low prothrombin rate 45
Elevated lacticodehydrogenase 100
Macrovacuolar or microvacuolar steatosis 100230
apoptotic activity of carnitine in CD4-positive lymphocytes
from peripheral blood of HIV-infected patients [56]. Samples
analysed after treatment by daily infusions of L-carnitine show
a decreased number of apoptotic cells that correlates with a
drop in ceramide concentration.
Hypertriglyceridaemia is a disorder commonly related to the
use of NRTIs [57]. The underlying mechanism involves mito-
chondrial impairment and would preferentially target hepato-
cytes. In a preliminary study, L-carnitine dramatically reversed
antiretroviral therapy-related hypertriglyceridaemia in HIV-
infected adults [58]. Reversal of lactic acidosis related to
NRTIs after treatment including L-carnitine has also been
reported in patients with blood lactate above 10mmol/l at the
beginning of the treatment [43,59].
L-carnitine as a potential treatment for life-threatening
NRTI-induced lactic acidosis
Carnitine is an important compound for the mitochondria
bioenergetic system that may modulate apoptosis. It has also
been observed that carnitine could reverse the mitochondrial
toxicity of NRTIs in vitro and in vivo [44,55,58,59].
In an attempt to define whether L-carnitine could be an effec-
tive treatment for patients with life-threatening NRTI-related
lactic acidosis, we prospectively investigated the effects of L-
carnitine in six critically ill, HIV-infected patients [43]. These
patients had arterial blood lactate above 10mmol/l and
severe organ dysfunction, possibly requiring dialysis. L-carni-
tine was used as a specific treatment, with a dosing regimen
of 50 or 100mg/kg per day if continuous dialysis was
required. Six patients received the treatment according to the
protocol. With a mean Simplified Acute Physiology Score II
score of 81, with blood lactate levels ranging from 13 to
20.1mmol/l and with pH values between 7.3 and 6.7, these
patients had a predicted intrahospital death probability of
91% [60]. When available, carnitine dosages revealed a
decrease in the free cartinine:total serum carnitine ratio and
an increase in urine excretion, features commonly encoun-
tered in this setting. Three patients out of six survived. Their
arterial blood lactate level returned to baseline within 15 days
and no increase in blood lactate was noted during the fol-
lowup. These preliminary results suggest that L-carnitine may
be useful for the treatment of life-threatening lactic acidosis
related to the use of NRTIs.
Conclusion
Following the widespread use of NRTIs for the treatment of
HIV-infected patients, increasing evidence has demonstrated
that these drugs can induce mitochondrial dysfunction and
lactic acidosis. Experimental data show that NRTIs alter mito-
chondrial breathing at different steps [1]. Increased lactaci-
daemia induced by NRTIs is explained by a shift toward
anaerobic metabolism with inverted lactate:pyruvate ratio
[36], by increased apoptosis leading to lactate overproduc-
tion, and by decreased lactate clearance secondary to
hepatic dysfunction [28]. The pathophysiology of NRTI-
induced acidosis might be even more complex, and genetic
risk factors could also play a role.
Despite increased physician awareness of NRTI-related
lactate overproduction, clinical features are so aspecific that
lactic acidosis can rapidly progress to life-threatening condi-
tions before NRTIs are withdrawn. In NRTI-related lactic aci-
dosis, the blood lactate concentration, a potential marker of
mitochondrial impairment, seems to have a highly significant
prognostic value. Whereas some workers consider mitochon-
drial cytopathy severe if blood lactate levels are above
5mmol/l [26], we have found that arterial blood lactate at the
time of diagnosis can predict outcome and that patients with
lactate levels above 9mmol/l are likely to develop life-threat-
ening NRTI-induced lactic acidosis and die [43].
Very few HIV-infected patients with severe lactic acidosis
have survived with the use of specific therapies [22,25]. Con-
sidering the rationale for the use of L-carnitine to treat NRTI-
induced severe lactic acidosis and related organ failures, we
conducted a small open trial of L-carnitine in critically ill
patients and reported survival of three out of six patients with
initial lactate levels above 9mmol/l [43]. Several drugs have
been proposed for the treatment of symptomatic lactic acido-
sis related to NRTIs because of their antiapoptotic and meta-
bolic effects. Nevertheless, these promising data are very
preliminary. Added to other studies, this preliminary result
suggests that L-carnitine is a potential treatment for NRTI-
induced mitochondrial dysfunction with severe lactic acido-
sis, although additional data should be provided to determine
its efficiency.
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